What is HS 300390?
HS 300390 classifies bulk medicaments that do not contain antibiotics, hormones, alkaloids, or their derivatives as active ingredients. This makes it a catch-all heading for a wide range of formulated pharmaceutical compounds traded in pre-retail form — meaning they are not yet packaged for end consumers but are destined for further manufacturing, compounding, or institutional dispensing.
End markets include pharmaceutical manufacturers incorporating these compounds into finished dosage forms, hospital pharmacies managing bulk therapeutic inventories, compounding pharmacies preparing customised formulations, and research institutions conducting clinical or preclinical work. Because demand is driven by therapeutic necessity rather than discretionary purchasing, it is structurally inelastic — volumes do not contract sharply during economic downturns, but they are acutely sensitive to supply disruptions and regulatory changes.
Classification note: Importers should take care to distinguish HS 300390 from adjacent headings covering antibiotics (3004.10), hormones (3004.32–3004.39), and alkaloid-based medicaments (3004.40). Misclassification at the heading level triggers duty miscalculation and potential customs holds — both costly outcomes in time-sensitive pharmaceutical supply chains.
Top Sourcing Countries for Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal)
India and China together dominate global supply of HS 300390, reflecting their established positions as the world's leading active pharmaceutical ingredient (API) manufacturers. Both countries offer structurally cost-competitive production due to large-scale chemical synthesis infrastructure, lower labour costs relative to Western markets, and deep integration across the API-to-formulation value chain.
India is particularly significant for generic pharmaceutical compounds, with a large base of FDA-approved and WHO-GMP-certified manufacturing facilities. Indian exporters are often cost-advantaged on a unit basis and benefit from long-standing regulatory acceptance in US and EU markets — though country-of-origin verification and facility-level audit trails remain essential for compliant importation.
China supplies a substantial share of the raw API feedstock that underpins Indian and global pharmaceutical manufacturing, making it a dual-layer risk factor: directly as an exporter of finished bulk compounds, and indirectly as an upstream supplier to other origin countries. Supply concentration in China introduces geopolitical and logistical vulnerability that procurement teams must actively manage.
Germany and Switzerland represent premium sourcing origins, particularly for high-complexity or patented compounds where regulatory pedigree, batch traceability, and quality documentation justify a materially higher unit cost. These origins are favoured by buyers operating under strict EMA frameworks or supplying regulated hospital formularies.
The United States exports bulk pharmaceutical compounds primarily to allied markets and within multinational supply chains, often at a cost premium but with strong regulatory alignment for FDA-regulated end uses.
Import Duty Rates and Trade Agreements
Duty rates for HS 300390 vary significantly by importing country and applicable trade agreement. MFN rates in major markets range from zero to moderate levels, but preferential rates under agreements such as the EU-India trade negotiations (in progress), ASEAN frameworks, and bilateral agreements involving Switzerland can materially reduce landed costs. Importers should verify current applicable rates with their national customs authority, as pharmaceutical tariff schedules are subject to periodic review and autonomous suspensions in several jurisdictions. Always confirm classification at the subheading level in the destination country, as national tariff schedules may subdivide 300390 further.
Cost Drivers and Price Outlook
The primary cost driver for HS 300390 is API raw material pricing, which is itself influenced by upstream chemical feedstock costs, energy inputs, and manufacturing yield rates. While bulk pharmaceuticals are not directly energy-sensitive in the same way as metals or petrochemicals, energy costs for synthesis and purification processes do flow through to API pricing over time. Crude oil benchmarks — Brent was tracking around $69/bbl and WTI near $64/bbl as of early 2026 — influence solvent and packaging input costs across the supply chain.
Currency dynamics are a material pricing variable. INR and CNY movements against the USD directly affect the competitiveness of Indian and Chinese exporters on global markets. Buyers negotiating longer-term supply contracts should build FX adjustment clauses into agreements, particularly given the volume of trade invoiced in USD from non-dollar economies. Regulatory compliance costs — including GMP audits, documentation requirements, and pharmacovigilance obligations — are rising in both the US and EU, adding a structural upward cost pressure that is unlikely to reverse.
Compliance and Sourcing Considerations
Transshipment risk for HS 300390 is rated medium. This reflects the reality that some bulk pharmaceutical compounds move through intermediate trade hubs — including UAE, Singapore, and Hong Kong — before reaching their declared destination. For importers subject to FDA or EMA oversight, the country of manufacture (not just country of export) must be verified and documented. Transshipped goods that obscure origin can trigger serious compliance consequences, including import alerts and facility delistings.
Country-of-origin verification is non-negotiable in this category. Buyers should require Certificates of Analysis, GMP certificates, and facility registration numbers from suppliers at the point of onboarding — not after a shipment arrives. For US importers, FDA establishment registration and Drug Master File references are standard due diligence checkpoints. For EU importers, EMA-aligned GMP certification and qualified person oversight requirements apply.
How to Source Bulk Pharmaceutical Compounds (Non-Antibiotic/Non-Hormonal) Efficiently
Effective procurement of HS 300390 requires treating supplier qualification as a continuous process, not a one-time event. Key actions for procurement managers and customs agents include:
- Maintain an approved supplier list with documented GMP audit dates, facility registration numbers, and regulatory standing in your target import market.
- Diversify supply origins across at least two geographies to reduce single-source exposure — particularly given the high concentration risk associated with Indian and Chinese API supply.
- Use trade intelligence data to monitor shipment flows, identify new suppliers entering your market, and benchmark competitor sourcing patterns before committing to long-term contracts.
- Build FX review cycles into procurement calendars to capture favourable INR or CNY movements when negotiating forward pricing.
- Verify HS classification at subheading level with your customs broker before each new product introduction — misclassification in pharmaceutical categories carries both financial and reputational penalties.
- Request batch-level documentation — including Certificate of Analysis, Certificate of Origin, and stability data — as standard shipment requirements, not exceptions.
Get a free sourcing intelligence report for HS 300390 at Logitality.com